Adakveo for SCD Being Tested in Series of Trials, Including at Higher Dose and in Children
Novartis is continuing to test Adakveo, approved to treat pain crises in sickle cell, at a higher dose, in kids, and in those with specific complications. Click here to learn more.
Did you enjoy this article?
Sorry, there were no replies found.
Log in to reply.